Europe (WHO region) vs Oman: New cases tested for RR-/MDR-TB
Europe (WHO region)
88.0%
in 2024
Oman
100.0%
in 2024
Europe (WHO region) rank
3rd
Oman rank
1st
New cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Oman
How they compare
Oman currently reports 100.0% against 88.0% in Europe (WHO region), a difference of 12.0%.
That makes Oman's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 8 times across 20 shared years of data; in 2005 it was Oman ahead.
Europe (WHO region) ranks 3rd and Oman ranks 1st of 11 groups.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 47.2% | 71.2% | 24.0% | Oman |
| 2010s | 84.6% | 95.9% | 11.3% | Oman |
| 2020s | 90.8% | 91.2% | 0.4% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher new cases tested for rr-/mdr-tb, Europe (WHO region) or Oman?
- Oman, at 100.0% against 88.0% in Europe (WHO region) as of 2024.
- What is the difference in new cases tested for rr-/mdr-tb between Europe (WHO region) and Oman?
- 12.0%, with Oman ahead.
- How many years of comparable data are there for Europe (WHO region) and Oman?
- 20 years are reported by both, from 2005 to 2024.
- How do Europe (WHO region) and Oman rank globally for new cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 3rd and Oman ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as New cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.